Boosted Lexiva With Lovaza Adjunctive Therapy in Hypertriglyceridemic, HIV-Infected Subjects (BuLLET)

This study has been completed.
Information provided by (Responsible Party):
Felizarta, Franco, M.D. Identifier:
First received: November 9, 2009
Last updated: March 26, 2012
Last verified: March 2012
Results First Received: March 26, 2012  
Study Type: Interventional
Study Design: Endpoint Classification: Efficacy Study;   Intervention Model: Single Group Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Conditions: Hypertriglyceridemia
HIV Infection
Interventions: Dietary Supplement: Lovaza
Drug: fosamprenavir/ritonavir

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
Boosted Lexiva With Lovaza No text entered.

Participant Flow:   Overall Study
    Boosted Lexiva With Lovaza  
STARTED     36  
COMPLETED     31  

  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
Boosted Lexiva With Lovaza No text entered.

Baseline Measures
    Boosted Lexiva With Lovaza  
Number of Participants  
[units: participants]
[units: participants]
<=18 years     0  
Between 18 and 65 years     36  
>=65 years     0  
[units: years]
Mean (Standard Deviation)
  48.3  (6.9)  
[units: participants]
Female     1  
Male     35  
Region of Enrollment  
[units: participants]
United States     36  

  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Proportion of Subjects With Triglycerides <200 mg/dL   [ Time Frame: 24 weeks ]

2.  Secondary:   Proportion of Subjects With HIV-1 RNA <50 Copies/mL   [ Time Frame: 24 weeks ]

  Serious Adverse Events

  Other Adverse Events
  Hide Other Adverse Events

Time Frame No text entered.
Additional Description No text entered.

Frequency Threshold
Threshold above which other adverse events are reported   1%  

Reporting Groups
Boosted Lexiva With Lovaza No text entered.

Other Adverse Events
    Boosted Lexiva With Lovaza  
Total, other (not including serious) adverse events    
# participants affected / at risk     6/36 (16.67%)  
Gastrointestinal disorders    
diarrhea *  
# participants affected / at risk     1/36 (2.78%)  
# events     1  
Infections and infestations    
influenza *  
# participants affected / at risk     1/36 (2.78%)  
# events     1  
Metabolism and nutrition disorders    
# participants affected / at risk     4/36 (11.11%)  
# events     4  
* Events were collected by non-systematic assessment

  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

  More Information